Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study

被引:81
作者
Badri, Motasim [1 ]
D Lawn, Stephen
Wood, Robin
机构
[1] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa
[2] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Clin Res Unit, London WC1, England
基金
英国惠康基金;
关键词
D O I
10.1016/S0140-6736(06)69117-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In sub-Saharan Africa, data for short-term risk of AIDS or death, which might inform decisions about when to start antiretroviral therapy (ART), are scarce. Our aim was to investigate these risks in patients who had no access to ART or who were given zidovudine alone. Methods 6-month risks (%) of death, AIDS, and combined risk of AIDS and death (AIDS/death) were calculated according to CD4-cell count category of less than 200 cells per mu L, 200-350 cells per mu L, or greater than 350 cells per mu L, stratified by WHO clinical stages I and 2 combined, 3, or 4 in untreated patients (n=1399) seeking care in tertiary public-sector HIV clinics before widespread availability of ART in Cape Town, South Africa. Findings Risk of death for WHO stages 1 and 2 was 3.5% for those with less than 200 cells per mu L, 2.8% for 200-350 cells per mu L, and 1.2% for greater than 350 cells per mu L. The corresponding rates for WHO stage 3 were 10.8%, 4.3%, and 4.9% and for stage 4, 22.2%, 10.3%, and 13.8%. 52% (90) of deaths took place in patients without AIDS. 6-month risk of AIDS for WHO stages 1 and 2 was 3.5% for those with less than 200 cells per mu L, 1.6% for 200-350 cells per mu L, and zero for greater than 350 cells per mu L. The corresponding rates for those with WHO stage 3 disease were 17.4%, 7.0%, and 2.2%. Interpretation In this study, risk of AIDS in patients with a CD4-cell count of less than 200 cells per mu L or greater than 350 cells per mu L was similar to that previously reported from European cohorts, but was 1.9 times greater for those with CD4-cell counts of between 200 and 350 cells per mu L. The high death rate before development of AIDS and a high risk of AIDS in those with CD4-cell counts of 200-350 cells per mu L indicate that delay in initiation of ART is associated with increased morbidity and mortality. These findings might help to amend criteria for start of ART in resource-limited settings.
引用
收藏
页码:1254 / 1259
页数:6
相关论文
共 34 条
[1]   Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients [J].
Alabi, AS ;
Jaffar, S ;
Ariyoshi, K ;
Blanchard, T ;
van der Loeff, MS ;
Awasana, AA ;
Corrah, T ;
Sabally, S ;
Sarge-Njie, R ;
Cham-Jallow, F ;
Jaye, A ;
Berry, N ;
Whittle, H .
AIDS, 2003, 17 (10) :1513-1520
[2]  
[Anonymous], EUR GUID CLIN MAN TR
[3]  
[Anonymous], 2003, SCAL ANT THER RES LT
[4]   Cost-effectiveness of highly active antiretroviral therapy in South Africa [J].
Badri, M ;
Maartens, G ;
Mandalia, S ;
Bekker, LG ;
Penrod, JR ;
Platt, RW ;
Wood, R ;
Beck, EJ .
PLOS MEDICINE, 2006, 3 (01) :48-56
[5]   Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines [J].
Badri, M ;
Bekker, LG ;
Orrell, C ;
Pitt, J ;
Cilliers, F ;
Wood, R .
AIDS, 2004, 18 (08) :1159-1168
[6]   Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study [J].
Badri, M ;
Wilson, D ;
Wood, R .
LANCET, 2002, 359 (9323) :2059-2064
[7]  
Beral V, 2004, AIDS, V18, P51, DOI [10.1097/01.aids.0000096908.73209.5d, 10.1097/00002030-200401020-00006]
[8]  
Bodri M, 2006, ANTIVIR THER, V11, P63
[9]   Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings - Efficiency related to active case finding [J].
Bogaards, JA ;
Weverling, GJ ;
Zwinderman, AH ;
Bossuyt, PMM ;
Goudsmit, J .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (02) :232-237
[10]  
*BRIT HIV ASS, 2005, BHIVA GUID TREATM HI